Review: patients with infectious mononucleosis have long lasting fatigue, and poor physical functioning predicts delayed recovery


QUESTION: In patients with infectious mononucleosis (IM), how frequent are chronic symptoms? Are any risk factors associated with chronic symptoms? Which interventions, if any, are preventive?

Data sources
Studies were identified by searching Medline, EMBASE/Excerpta Medica, PsycINFO, and CINAHL (to October 2001) and the Science and Social Sciences citation indices (to November 2001). The references of retrieved studies were checked.

Study selection
English language studies were selected if they were cohort or intervention studies that explored the course of illness for >6 weeks after onset in uncomplicated IM.

Data extraction
A standard form was used to extract data on study design and methods, setting, patient characteristics, study purpose, definition of IM, ill health and recovery, predictors of delayed recovery, and main study outcomes.

Main results
16 articles of 14 studies (2 randomised controlled trials [RCTs], 1 quasi-RCT, 7 prospective cohort studies, and 4 retrospective cohort studies) were included. Sample sizes ranged from 25–357 patients, and follow up ranged from 2 months to 2 years. 5 studies reported <80% follow up and are not included in this abstract. 5 studies examined the course of illness. In 1 prospective study, patients recovering from IM were more likely than those with upper respiratory tract infections (URTIs) to have fatigue (40% vs 15%), hypersomnia (22% vs 2%), or chronic fatigue syndrome (9–22% vs 0–6%) at 6 months. A quasi-RCT reported that fatigue was the longest lasting symptom; 10% of patients reported not being recovered by 6 weeks. 1 retrospective study reported patients with continued symptoms at 6 months (56%) and 11 months (16%) with fatigue as the most persistent symptom; in another retrospective cohort study, only 1.5% of patients at a student health clinic had fatigue that persisted 2 months after onset. In 1 prospective study, psychiatric disorders were increased at onset but not at 6 months. A small retrospective study reported increased depression (40% absolute increase) and anxiety (10% absolute increase) in women 12 months after infection, but no increase in men was seen.

2 of 4 studies found no association between clinical features and poor outcome. Delayed recovery was predicted by splenomegaly at onset in 1 study (1 study found no association). Cervical lymphadenopathy was associated with fatigue syndrome at 1 and 2 months (1 study). In 4 studies of psychological predictors, a history of depression was not associated with poor outcome (1 study); social adversity predicted psychiatric diagnosis at 2 and 6 months (1 study); psychological comorbidity was associated with delayed recovery at 6 months (1 retrospective study); and a premorbid mood disorder predicted fatigue syndrome at 6 months (1 study). In 2 studies of demographic predictors, female sex was associated with psychological distress in recovery (1 study); 1 study showed that sex did not predict poor outcome. In 4 studies of behavioural variables, predictors for delayed recovery included bed rest (1 quasi-RCT), longer absence from school or work (1 retrospective study), and physical deconditioning (1 study). In 2 RCTs, acyclovir alone or combined with prednisolone did not reduce chronic symptoms.

Conclusions
In patients with infectious mononucleosis, the chronic symptom of fatigue is reported by up to one half of patients. Evidence for clinical and psychological predictors is mixed, but poor physical functioning consistently predicts delayed recovery. Drug therapy does not shorten recovery time.

COMMENTARY
Infectious mononucleosis is usually managed as a benign self limited illness, and many patients currently receive no follow up visits. The review by Candy et al suggests that some people may have persistent fatigue and other symptoms for up to 6 months. The studies reviewed had many methodological weaknesses. Only one had both a comparison group (patients with URTI) and a loss to follow up of <20%. This study also had the advantage of being done in a primary care setting, thus avoiding the selection bias of many of the studies that recruited subjects only from student health settings. None the less, this study found the highest rate of persisting fatigue and showed that patients assessed 6 months after the onset of IM were also more likely to have chronic fatigue syndrome (CFS) as measured by 2 previously validated scales.

How should these findings change practice? Since clinical features of the initial IM infection do not predict prognosis, regular follow up assessment visits for all patients might be useful. Patients whose symptoms persist for >6 months may meet the criteria for CFS, and could then benefit from interventions such as graded exercise or cognitive behaviour therapy (CBT). Those whose fatigue has persisted for <6 months (and thus do not meet the Centers for Disease Control and Prevention case definition) might also benefit from one of these interventions. The association noted in this review between poor physical functioning at the onset of IM and the presence of prolonged symptoms suggests that early initiation of a graded exercise programme might be helpful. The role of CBT in early management is more speculative, and the review did not address coping strategies or disease attributions as predictors of ongoing symptoms.

Lorna A Becker, MD
SUNY Upstate Medical University
Syracuse, New York, USA